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Abstract 
High prevalence of HBV and HCV infections in prisoners suggests them as one of the main infection source in community.  
Preventive measures can possibly decrease their rate of infection and infectivity. We evaluated prevalence of HBV and 
HCV infections and their relation to dangerous behavior in addict prisoners. This was a cross-sectional study included pris-
oners of central provinces of Iran who were evaluated for HBV and HCV in 2003. All of 1431 prisoners filled out question-
naires that were evaluated for HBsAg and HCV antibody. There were 51 prisoners (3.5%) who were HBsAg positive and 
513 prisoners (35.8%) had HCV antibody. Odd`s ratio for HBV and HCV were 10.3 and 9.6 for IVDA, respectively. This 
study showed that the HBV and specially HCV infection had high prevalence among prisoners. In comparison to rate of 
HBsAg and HCV infection in general population of Iran, this study showed that the HBsAg was 2 times and HCV infection 
was 70 times more frequent in prisoner than in general population of Iran. The education for dangerous behavior is strongly 
recommended to control this persistent infection source for hepatitis B and C in the community. 
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Introduction  
Hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infections are one of the major health 
problems in the world (1). In previous studies, it 
had been estimated that HBsAg carrier rate was 
about 3% in Iran (2). According to the recent 
Iranian national health survey, the prevalence 
of HBV infection is 1.7% in the country (3). 
In addition, world prevalence of HCV infection 
is 1% (2). Earlier studies in Iran put HCV preva-
lence rate at about 0.3% (2). However, it seems 
that its prevalence is increasing in the country; 
and in a recent study, 0.46% of Iranian blood 
donors were HCV positive (4). 
Viral hepatitis B and C infections have been com-
mon diseases during recent decades. These diseases 
take place via similar routes of transmission, and 
population affected are such as intravenous drug 
users (IVDU), hemophilia, dialysis patients, and 
health care workers (5). In addition, these infec-
tions are more prevalence in some other high-risk 
groups like gypsies than normal population. One 
study showed that they were 10 times more fre-
quent in gypsies than in general population (6). 
Beside to mention groups another high-risk group 
is prisoners. It is estimated by Centers for Dis-
ease Control, about 8 millions prisoners return 
to community annually that may be dangerous 
for community health. In addition, Up to 35% 
of prisoners have history of addition. (7-11). In 
returning to community, they may have a major 
role to transmit these infections to others. There 
are many studies which indicate a high prevalence 
of HBV, HCV infection among prisoners.13%-
47% of prisoners in the USA had HBV infection 
(12). 57.7% of Australian prisoners had HCV 
infection (13) that was 2-6 times more than its 
prevalence in the community (12). Likewise, 
68% and 65% of addict prisoners are infected 
with HBV and HCV infection, respectively (14). 
The communities of prisoners are characterized 
by pervasive social health problems, illegal be-
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havior, and limited educational opportunities. 
Because of different life style, they might be ex-
posed to multiple sexual partners, addiction and 
various kinds of infections. There have been lim-
ited studies dealing with their health status in Iran. 
Epidemiologic studies of HBV and HCV infec-
tion among prisoners population are very impor-
tant, as they can become a potential source of 
these communicable diseases. 
Consequently, the prevalence rate of HBV and 
HCV infections and their relation to dangerous 
behavior in addict prisoners were the main pur-
poses of this study. 
 
Materials and Methods 
In this study, we evaluated Jails of the 3 central 
provinces of Iran including Isfahan, Lorestan 
and Chaharmahal VA Bakhtiari in 2003. Our 
target population included all male prisoners 
who were arrested because of their addiction. In 
these three Jails, 1898 prisoners were selected 
randomly and classified by duration of being in 
prison. All of 1431 questionnaires were filled 
out by prisoners. These questionnaires had been 
confirmed for validity and contents by a psy-
chiatrist, social medicine specialist, and infec-
tious disease specialist. The reliability of ques-
tionnaires were calculated in 30 prisoners (re-
sults included in this results) that showed cron-
bach`s alpha of 88%. Then the blood samples 
were taken and sera were sent to reference blood 
bank laboratory where the tests were done. Used 
kit (Made by Italian Diasorin Company) had 
specificity and sensitivity more than 90%. All 
of the positive tests were repeated and done by 
the same laboratory, instrument, and specialist. 
The results were considered negative, suspected, 
and positive, if they were less than 1, between 1 
to 1.2 and more than 1.2, respectively. 
The collected data were analyzed by logistic 
tests and with SPSS program. This paper was 
conducted in Infectious and Tropical Diseases 
Research Center affiliated to Isfahan University 
of Medical Sciences and Department of Infec-
tious Diseases of Shahr-e-kord University of 
Medical Sciences, Iran. 
 
Results 
Our results showed that 51 prisoners (3.5%) 
had HBsAg positive and 513 (35.8%) had HCV 
antibody. According to the age, mostly HBsAg 
carrier and HCV infection has been occurred in 
prisoners younger than 30 yr old (Table 1). Sus-
pected titers of HBsAg were seen in 14 prisoners 
(0/97%) and HCV antibody in 137 prisoners (9.5%). 
58.8% and 62.2% of the prisoners with HBsAg 
and HCV infections had one or more high-risk 
behaviors. The most common dangerous behaviors 
were as follows: Previous addiction (80.5%), tattoo-
ing (50.7%), needle sharing (36%), current addic-
tion (28.3%), and I.V drug abusers (IVDA) (28%). 
Totally, 903 of the prisoners had been impris-
oned for less than 1 yr, 621 (43.4%) for their 
first time but 323(22.6%) for at least 4 times. 
Odd`s ratio for HBV and HCV infections were 
10.3 and 9.6 in IVDA, (P< 0.001 and P< 0.05) 
respectively. Odd`s ratio for HBV and HCV infec-
tions were 2.4 and 4, in being in prison between 
1-5 yr (P< 0.001 and P< 0.005), respectively. In 
addition odd`s ratio for HBV and HCV infec-
tions were 2.9 and 6.3, in being in prison more 
than 5 yr (P< 0.001 and P< 0.01), respectively. 
 
Table 1: Distributions of HBsAg and HCV-Ab by age and province 
 
Isfahan Lorestan Chaharmahal va Bakhtiari 
HBsAg HCV-Ab HBsAg HCV-Ab HBsAg HCV-Ab 
 
 
Age (yr) 
n % n % n % n % n % n % 
< 30 8 53.3 79 38.5 14 53.8 117 50 3 30 40 53.3 
31-40 6 40 67 32.7 8 30.8 80 34.5 3 30 19 25.3 
> 41 1 6.7 59 28.8 4 15.4 36 15.5 4 40 16 21.4 
Total 15 100 205 100 26 100 233 100 10 100 75 100 
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Discussion 
In comparison to rate of HBsAg and HCV in-
fection, in general population of Iran, this study 
showed that the HBsAg was 2 times and HCV 
infection was 70 times more frequent. Similar 
to our study, one third of the prisoners had been 
reported to have HBV and HCV infections (9). 
The prevalence of  HBV and HCV infections were 
shown to be 6% and 22% in Irish prisoners 
(10), 61.1% and 82.2% in IVDA of Mexicans 
jails (15) 20.2% and 23.1% among males in 
Rhode Island prisons (11) and 25.2% and 29.7%, 
(12) 64% and 87% among IVDA Danish prison-
ers (16). In addition, this rate would reach up to 
30% for HCV infection in British prisoner (1), 
57.5% in Australian correctional facilities (13) 
and 37% of prisoners (17). Even some of them 
had chronic HBV infection (12). All these studies 
show the importance of this issue. 
The greatest threat in our study was for the IVDA, 
as their odd`s ratio for HBV and HCV infection 
were 10.3 and 9.6, respectively. The odd's ratio 
for males in Rhode Island prisons, for hepatitis B 
and C were 7.9 and 32.4, respectively (18). 
The high prevalence of HBV and HCV infec-
tions of these studies summarized their perma-
nent infectivity, especially among IVDA pris-
oners (19) who can be as a source for commu-
nity after freedom. Inadequate information of the 
prisoners about dangerous behaviors for HBV 
and HCV infections that is less than 20% (16), 
along with incomplete attention to preventive 
measures has caused that less than 2% of prison-
ers had been vaccinated against HBV (20).  
Considering the results of this study, education 
for dangerous behavior along with screening, 
vaccination, and appropriate treatment against 
hepatitis that are demonstrated to be cost benefit 
(21- 23) is strongly recommended to control this 
persistent infection source for HBV and HCV 
in the community. 
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